ViiV’s Triumeq offers added benefit for treatment-naive adults with HIV, says IQWiG

8 January 2015

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a dossier on dolutegravir in spring 2014, has now examined in another dossier of the fixed-dose combination of dolutegravir/abacavir/lamivudine, marketed by ViiV Healthcare as Triumeq, to assess whether the drug combination also offers an added benefit over the appropriate comparator therapy. ViiV Healthcare is a joint venture majority owned by GlaxoSmithKline (LSE: GSK), and partnered with Pfizer (NYSE: PFE) and Shionogi (TYO: 4507).

According to the findings, there is an indication that adults who have not been treated for their HIV infection have considerable added benefit from treatment with the new fixed-dose combination. However, an added benefit versus the appropriate comparator therapy is not proven for adults with antiretroviral pre-treatment and for adolescents with and without pre-treatment, because suitable study data are lacking.

No evaluable data for adolescents and pre-treated adults

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK